🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

8,395 results for “La” Clear

  1. Treatment of Respiratory Complications Associated with COVID-19, Influenza A, Metapneumovirus, Respiratory Syncytial Virus (RSV) Infection Using Wharton’s Jelly (WJ)-Umbilical Cord (UC) Mesenchymal Stromal Cells (ProTrans®): open Phase IB Clinical Trial

    Lacuna Pharma Pty Ltd

    Respiratory viral disease, COVID-19, Influenza A, Metapneumovirus, Respiratory syncytial virus Infection

    phase 1 other active

    1 trial

  2. Treatment of cancer with Immune Checkpoint Inhibition therapy boosted by High Intensity Focused Ultrasound Histotripsy (the iFOCUS study)

    Disc Medicine

    Metastatic or unresectable solid malignancies. Standard of care treatment options must not be available or not be considered feasible. Patients must have a primary tumor or metastasis that is suitable for HIFU-HT treatment.

    phase 1 other active

    1 trial

  3. Trebananib 3 mg/kg

    Takeda

    Neoplasms, Advanced Solid

    phase 1 small molecule completed

    1 trial

  4. Treprostinil Inhalation Powder

    United Therapeutics Europe Ltd

    Pulmonary Arterial Hypertension

    phase 1 small molecule completed

    1 trial

  5. Treprostinil diethanolamine

    United Therapeutics Europe Ltd

    Hypertension, Pulmonary

    phase 1 small molecule completed

    2 trials

  6. Trial of the novel peroral anti-tumor treatment in patients with solid tumors

    Lacuna Pharma Pty Ltd

    Metastatic or locally advanced solid tumors for which no standard therapy exists or standard therapy has failed: tumors of lung, head and neck, colon, stomach, esophagus, breast, ovary and/or fallopian tube or primary peritoneal high-grade serous carcinoma

    phase 1 other active

    1 trial

  7. Trial to evaluate the administration of IDOR-1134-2831 vaccine in healthy participants

    Lacuna Pharma Pty Ltd

    Clostridioides difficile (C. difficile)

    phase 1 other active

    1 trial

  8. Triamcinolone Acetonide Extended-Release Injectable Suspension

    Pacira Ireland Limited

    Osteoarthritis, Knee

    phase 1 small molecule completed

    1 trial

  9. Trichostatin A

    Vanda Pharmaceuticals Netherlands B.V.

    Relapsed or Refractory Hematologic Malignancies

    phase 1 small molecule active

    1 trial

  10. Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)

    Merck Sharp and Dohme

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  11. U96

    The First People's Hospital of Lianyungang

    Relapsed or Refractory B Cell Leukemia and Lymphoma

    phase 1 small molecule active

    1 trial

  12. UB-921

    United Therapeutics Europe Ltd

    Breast Neoplasm

    phase 1 mab completed

    1 trial

  13. UCMSC

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Bronchopleural Fistula

    phase 1 mab active

    1 trial

  14. UNEX-42

    United Therapeutics Europe Ltd

    Bronchopulmonary Dysplasia

    phase 1 mab terminated

    1 trial

  15. UT-15C SR (treprostinil diethanolamine)

    United Therapeutics Europe Ltd

    Pulmonary Arterial Hypertension

    phase 1 small molecule completed

    1 trial

  16. V920

    United Therapeutics Europe Ltd

    Ebola Virus

    phase 1 mab completed

    1 trial

  17. VEGF Trap

    Regeneron UK Limited

    Neovascular Age Related Macular Degeneration

    phase 1 small molecule completed

    1 trial

  18. VEGF Trap

    Regeneron UK Limited

    Macular Degeneration

    phase 1 small molecule completed

    1 trial

  19. VEGF Trap-Eye

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 1 small molecule completed

    1 trial

  20. VHX-896

    Vanda Pharmaceuticals Netherlands B.V.

    Healthy

    phase 1 small molecule completed

    1 trial

  21. VHX-896 and iloperidone

    Vanda Pharmaceuticals Netherlands B.V.

    Schizophrenia

    phase 1 small molecule completed

    1 trial

  22. VHX-896 and iloperidone

    Vanda Pharmaceuticals Netherlands B.V.

    Healthy

    phase 1 small molecule completed

    1 trial

  23. VLY-686

    Vanda Pharmaceuticals Netherlands B.V.

    Pruritus

    phase 1 small molecule completed

    1 trial

  24. VSA001 injection

    Arrowhead Pharmaceuticals Ireland Limited

    Healthy Adult Volunteers

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources